Raras
Buscar doenças, sintomas, genes...
Lipodistrofia generalizada congênita
ORPHA:528CID-10 · E88.1CID-11 · LD27.60DOENÇA RARA

Lipodistrofia caracterizada pela associação de lipoatrofia, hipertrigliceridemia, hepatomegalia e características acromegaloides. A BSCL pertence ao grupo das síndromes de resistência extrema à insulina, que também inclui o leprechaunismo, a síndrome de Rabson-Mendenhall, a lipodistrofia generalizada adquirida e a resistência à insulina dos tipos A e B.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Lipodistrofia caracterizada pela associação de lipoatrofia, hipertrigliceridemia, hepatomegalia e características acromegaloides. A BSCL pertence ao grupo das síndromes de resistência extrema à insulina, que também inclui o leprechaunismo, a síndrome de Rabson-Mendenhall, a lipodistrofia generalizada adquirida e a resistência à insulina dos tipos A e B.

Pesquisas ativas
5 ensaios
26 total registrados no ClinicalTrials.gov
Publicações científicas
352 artigos
Último publicado: 2026 Mar 23

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
1-9 / 1 000 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.5
Europe
Início
Childhood
+ infancy, neonatal
🏥
SUS: Cobertura mínimaScore: 20%
Centros em: PA, PR, SC, RS, ES +10CID-10: E88.1
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

📏
Crescimento
9 sintomas
🫃
Digestivo
9 sintomas
🦴
Ossos e articulações
8 sintomas
❤️
Coração
4 sintomas
🧬
Pele e cabelo
4 sintomas
🧠
Neurológico
3 sintomas

+ 22 sintomas em outras categorias

Características mais comuns

90%prev.
Hipertrofia do músculo esquelético
Muito frequente (99-80%)
90%prev.
Perda de tecido adiposo
Muito frequente (99-80%)
90%prev.
Resistência à insulina
Muito frequente (99-80%)
90%prev.
Hepatomegalia
Muito frequente (99-80%)
90%prev.
Lipodistrofia
Muito frequente (99-80%)
55%prev.
Hipertrigliceridemia
Frequente (79-30%)
69sintomas
Muito frequente (5)
Frequente (4)
Ocasional (24)
Muito raro (4)
Sem dados (32)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 69 características clínicas mais associadas, ordenadas por frequência.

Hipertrofia do músculo esqueléticoSkeletal muscle hypertrophy
Muito frequente (99-80%)90%
Perda de tecido adiposoAdipose tissue loss
Muito frequente (99-80%)90%
Resistência à insulinaInsulin resistance
Muito frequente (99-80%)90%
HepatomegaliaHepatomegaly
Muito frequente (99-80%)90%
LipodistrofiaLipodystrophy
Muito frequente (99-80%)90%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico352PubMed
Últimos 10 anos191publicações
Pico202026 papers
Linha do tempo
2026Hoje · 2026🧪 2006Primeiro ensaio clínico📈 2020Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

3 genes identificados com associação a esta condição. Padrão de herança: Autosomal recessive.

CAV1Caveolin-1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

May act as a scaffolding protein within caveolar membranes (PubMed:11751885). Forms a stable heterooligomeric complex with CAV2 that targets to lipid rafts and drives caveolae formation. Mediates the recruitment of CAVIN proteins (CAVIN1/2/3/4) to the caveolae (PubMed:19262564). Interacts directly with G-protein alpha subunits and can functionally regulate their activity (By similarity). Involved in the costimulatory signal essential for T-cell receptor (TCR)-mediated T-cell activation. Its bind

LOCALIZAÇÃO

Golgi apparatus membraneCell membraneMembrane, caveolaMembrane raftGolgi apparatus, trans-Golgi networkCytoplasm

VIAS BIOLÓGICAS (4)
SARS-CoV-2 targets host intracellular signalling and regulatory pathwaysSARS-CoV-1 targets host intracellular signalling and regulatory pathwaysExtra-nuclear estrogen signalingBasigin interactions
MECANISMO DE DOENÇA

Lipodystrophy, congenital generalized, 3

A form of congenital generalized lipodystrophy, a metabolic disorder characterized by a near complete absence of adipose tissue, extreme insulin resistance, hypertriglyceridemia, hepatic steatosis and diabetes mellitus. CGL3 inheritance is autosomal recessive.

OUTRAS DOENÇAS (6)
pulmonary hypertension, primary, 3partial lipodystrophy, congenital cataracts, and neurodegeneration syndromecongenital generalized lipodystrophy type 3heritable pulmonary arterial hypertension
HGNC:1527UniProt:Q03135
BSCL2SeipinDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Plays a crucial role in the formation of lipid droplets (LDs) which are storage organelles at the center of lipid and energy homeostasis (PubMed:19278620, PubMed:21533227, PubMed:30293840, PubMed:31708432). In association with LDAF1, defines the sites of LD formation in the ER (PubMed:31708432). Also required for growth and maturation of small nascent LDs into larger mature LDs (PubMed:27564575). Mediates the formation and/or stabilization of endoplasmic reticulum-lipid droplets (ER-LD) contacts

LOCALIZAÇÃO

Endoplasmic reticulum membraneLipid droplet

MECANISMO DE DOENÇA

Lipodystrophy, congenital generalized, 2

A form of congenital generalized lipodystrophy, a metabolic disorder characterized by a near complete absence of adipose tissue, extreme insulin resistance, hypertriglyceridemia, hepatic steatosis and early onset of diabetes. Inheritance is autosomal recessive.

OUTRAS DOENÇAS (5)
hereditary spastic paraplegia 17severe neurodegenerative syndrome with lipodystrophyneuronopathy, distal hereditary motor, type 5Ccongenital generalized lipodystrophy type 2
HGNC:15832UniProt:Q96G97
AGPAT21-acyl-sn-glycerol-3-phosphate acyltransferase betaDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Converts 1-acyl-sn-glycerol-3-phosphate (lysophosphatidic acid or LPA) into 1,2-diacyl-sn-glycerol-3-phosphate (phosphatidic acid or PA) by incorporating an acyl moiety at the sn-2 position of the glycerol backbone

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (2)
Synthesis of PAMLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
MECANISMO DE DOENÇA

Lipodystrophy, congenital generalized, 1

A form of congenital generalized lipodystrophy, a metabolic disorder characterized by a near complete absence of adipose tissue, extreme insulin resistance, hypertriglyceridemia, hepatic steatosis and early onset of diabetes. Inheritance is autosomal recessive.

OUTRAS DOENÇAS (1)
congenital generalized lipodystrophy type 1
HGNC:325UniProt:O15120

Variantes genéticas (ClinVar)

338 variantes patogênicas registradas no ClinVar.

🧬 CAV1: NC_000007.13:g.(?_116165117)_(117307162_?)del ()
🧬 CAV1: NM_001753.5(CAV1):c.436del (p.Arg146fs) ()
🧬 CAV1: GRCh38/hg38 7q31.1-31.2(chr7:113604778-117643891) ()
🧬 CAV1: NM_001753.5(CAV1):c.358G>A (p.Ala120Thr) ()
🧬 CAV1: GRCh37/hg19 7q31.1-31.2(chr7:108967155-116850770)x1 ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 466 variantes classificadas pelo ClinVar.

186
280
Patogênica (39.9%)
VUS (60.1%)
VARIANTES MAIS SIGNIFICATIVAS
BSCL2: NM_001122955.4(BSCL2):c.324_325del (p.Ser109fs) [Pathogenic]
BSCL2: NM_001122955.4(BSCL2):c.630+1G>T [Pathogenic]
ACTL6B: NM_016188.5(ACTL6B):c.1113+1G>T [Likely pathogenic]
CAVIN1: NM_012232.6(CAVIN1):c.1061_1091del (p.Glu354fs) [Likely pathogenic]
BSCL2: NM_001122955.4(BSCL2):c.512_519del (p.Arg171fs) [Likely pathogenic]

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
Aprovado1
3Fase 35
2Fase 22
·Pré-clínico3
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 11 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Lipodistrofia generalizada congênita

Centros de Referência SUS

24 centros habilitados pelo SUS para Lipodistrofia generalizada congênita

Centros para Lipodistrofia generalizada congênita

Detalhes dos centros

Hospital Universitário Prof. Edgard Santos (HUPES)

R. Dr. Augusto Viana, s/n - Canela, Salvador - BA, 40110-060 · CNES 0003808

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital Infantil Albert Sabin

R. Tertuliano Sales, 544 - Vila União, Fortaleza - CE, 60410-794 · CNES 2407876

Serviço de Referência

Rota
Anomalias CongênitasDeficiência Intelectual

Hospital de Apoio de Brasília (HAB)

AENW 3 Lote A Setor Noroeste - Plano Piloto, Brasília - DF, 70684-831 · CNES 0010456

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Estadual Infantil e Maternidade Alzir Bernardino Alves (HIABA)

Av. Min. Salgado Filho, 918 - Soteco, Vila Velha - ES, 29106-010 · CNES 6631207

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital das Clínicas da UFG

Rua 235 QD. 68 Lote Área, Nº 285, s/nº - Setor Leste Universitário, Goiânia - GO, 74605-050 · CNES 2338424

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital Universitário da UFJF

R. Catulo Breviglieri, Bairro - s/n - Santa Catarina, Juiz de Fora - MG, 36036-110 · CNES 2297442

Atenção Especializada

Rota
Anomalias Congênitas

Hospital das Clínicas da UFMG

Av. Prof. Alfredo Balena, 110 - Santa Efigênia, Belo Horizonte - MG, 30130-100 · CNES 2280167

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário Julio Müller (HUJM)

R. Luis Philippe Pereira Leite, s/n - Alvorada, Cuiabá - MT, 78048-902 · CNES 2726092

Atenção Especializada

Rota
Anomalias Congênitas

Hospital Universitário João de Barros Barreto

R. dos Mundurucus, 4487 - Guamá, Belém - PA, 66073-000 · CNES 2337878

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário Lauro Wanderley (HULW)

R. Tabeliao Estanislau Eloy, 585 - Castelo Branco, João Pessoa - PB, 58050-585 · CNES 0002470

Atenção Especializada

Rota
Anomalias Congênitas

Instituto de Medicina Integral Prof. Fernando Figueira (IMIP)

R. dos Coelhos, 300 - Boa Vista, Recife - PE, 50070-902 · CNES 0000647

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Pequeno Príncipe

R. Des. Motta, 1070 - Água Verde, Curitiba - PR, 80250-060 · CNES 3143805

Serviço de Referência

Rota
Anomalias CongênitasDeficiência Intelectual

Hospital Universitário Regional de Maringá (HUM)

Av. Mandacaru, 1590 - Parque das Laranjeiras, Maringá - PR, 87083-240 · CNES 2216108

Atenção Especializada

Rota
Anomalias Congênitas

Hospital de Clínicas da UFPR

R. Gen. Carneiro, 181 - Alto da Glória, Curitiba - PR, 80060-900 · CNES 2364980

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário Pedro Ernesto (HUPE-UERJ)

Blvd. 28 de Setembro, 77 - Vila Isabel, Rio de Janeiro - RJ, 20551-030 · CNES 2280221

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira (IFF/Fiocruz)

Av. Rui Barbosa, 716 - Flamengo, Rio de Janeiro - RJ, 22250-020 · CNES 2269988

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital São Lucas da PUCRS

Av. Ipiranga, 6690 - Jardim Botânico, Porto Alegre - RS, 90610-000 · CNES 2232928

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital de Clínicas de Porto Alegre (HCPA)

Rua Ramiro Barcelos, 2350 Bloco A - Av. Protásio Alves, 211 - Bloco B e C - Santa Cecília, Porto Alegre - RS, 90035-903 · CNES 2237601

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário da UFSC (HU-UFSC)

R. Profa. Maria Flora Pausewang - Trindade, Florianópolis - SC, 88036-800 · CNES 2560356

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital das Clínicas da FMUSP

R. Dr. Ovídio Pires de Campos, 225 - Cerqueira César, São Paulo - SP, 05403-010 · CNES 2077485

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital de Base de São José do Rio Preto

Av. Brg. Faria Lima, 5544 - Vila Sao Jose, São José do Rio Preto - SP, 15090-000 · CNES 2079798

Atenção Especializada

Rota
Anomalias Congênitas

Hospital de Clínicas da UNICAMP

R. Vital Brasil, 251 - Cidade Universitária, Campinas - SP, 13083-888 · CNES 2748223

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital de Clínicas de Ribeirão Preto (HCRP-USP)

R. Ten. Catão Roxo, 3900 - Vila Monte Alegre, Ribeirão Preto - SP, 14015-010 · CNES 2082187

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

UNIFESP / Hospital São Paulo

R. Napoleão de Barros, 715 - Vila Clementino, São Paulo - SP, 04024-002 · CNES 2688689

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo
Sobre os centros SUS: Estes centros são habilitados pelo Ministério da Saúde como Serviços de Referência em Doenças Raras ou Serviços de Atenção Especializada. O atendimento é pelo SUS, com encaminhamento da rede de atenção básica.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

3 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

26 ensaios clínicos encontrados, 5 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
186 papers (10 anos)
#1

Lipodystrophies in Clinical Practice: A Case Series From a Local Health Unit in Portugal.

Cureus2026 Feb

Background Lipodystrophies are rare disorders characterized by loss of adipose tissue, leading to severe metabolic and multisystem complications. Data on real-world management remain limited, particularly in Portugal. Objectives The objective of this study is to describe the clinical, metabolic, genetic, and therapeutic characteristics of patients with confirmed or suspected lipodystrophy followed at a Portuguese Endocrinology Outpatient Clinic. Methods We conducted a retrospective observational study including 21 patients with clinical suspicion or diagnosis of lipodystrophy. Demographic, clinical, laboratory, imaging, and genetic data were collected. Results The cohort was predominantly female (90.5%) with a median age at diagnosis of 49 years. Sixteen patients (76.2%) had familial partial lipodystrophy (FPLD), two (9.5%) had congenital generalized lipodystrophy, two (9.5%) had acquired generalized lipodystrophy, and one presented a complex syndromic form. Diabetes mellitus was present in 71.4% of patients and hypertriglyceridemia in 52.4%. Metabolic liver disease occurred in both generalized and partial forms. Autoimmune disorders affected 31.6% of patients, and cardiac involvement was observed in 23.8%. Genetic testing identified pathogenic or likely pathogenic variants in BSCL2 and PPARG in three patients, while most FPLD cases remained genetically unexplained. Metreleptin therapy in three patients with generalized lipodystrophy improved glycemic control, triglycerides, liver enzymes, and proteinuria. Dual-energy X-ray absorptiometry imaging supported the phenotypic characterization of adipose tissue loss. Conclusions Detailed physical examination, genetic testing, imaging, and early therapeutic interventions are critical for management. These findings align with European registry data and highlight the need for increased awareness and systematic evaluation in real-world clinical practice.

#2

Berardinelli-Seip syndrome.

Endokrynologia Polska2026

Berardinelli-Seip syndrome, also known as congenital generalized lipodystrophy (CGL), is a rare genetic disorder characterized by lipoatrophy, acromegaloid features, hyperinsulinemia, hypertriglyceridemia, and hepatic steatosis. With estimated prevalence 1 in every 10,000,000 births, CGL challenges medical specialists to seek better ways for early diagnosis of the disease. Despite its rarity, the condition is associated with severe metabolic and cardiovascular complications, leading to significant morbidity and reduced life expectancy. Advances in molecular genetics have identified mutations in AGPAT2, BSCL2, CAV1, and PTRF, which provide important insights into adipose tissue biology and systemic metabolism. Early recognition and genetic confirmation are crucial to initiate timely interventions, including lifestyle modification, insulin sensitizers, and lipid-lowering therapies including metreleptin therapy in indicated cases. Two illustrative cases are presented, reflecting our experience with the clinical variability, genetic findings, and therapeutic strategies in CGL as well as highlighting the importance of comprehensive care and emerging therapies.

#3

AGPAT2 acts at the crossroads of lipid biosynthesis and DRP1-mediated ER morphogenesis.

Nature communications2025 Dec 12

The morphology of the endoplasmic reticulum (ER), characterized by central sheets and peripheral tubules, is controlled by membrane-shaping proteins. However, the role of lipids in ER morphogenesis remains elusive, despite the ER being the major site for lipid synthesis. Here, by examining the role of eighteen phosphatidic acid (PA)-generating enzymes in ER morphology, we identify lysophosphatidic acid acyltransferase 2 (AGPAT2) as a critical factor in mouse and human cells. AGPAT2 produces PA in the glycerophospholipid/triacylglycerol biosynthesis pathway, and its mutations cause congenital generalized lipodystrophy. We find that AGPAT2-generated PA drives ER tubulation through gene knockout, 3D structural analysis by FIB-SEM, super-resolution microscopy, lipidomics, AlphaFold, and in vitro reconstitutions of ER tubulation and AGPAT2 activity. AGPAT2 interacts with and supplies PA to the PA-binding, dynamin-related GTPase, DRP1, which subsequently tubulates the ER in a manner independent of GTP hydrolysis and oligomerization, distinct from its function in mitochondrial division. Consistently, the reduction of PA levels by ectopic expression of a PA phosphatase, LIPIN1, transforms ER tubules into sheets. Our results reveal an unforeseen interplay between lipid biosynthesis and membrane organization in the ER.

#4

The Role of the AGPAT2 Gene in Adipose Tissue Biology and Congenital Generalized Lipodystrophy Pathophysiology.

International journal of molecular sciences2025 Jun 05

1-Acylglycerol-3-phosphate O-acyltransferase (1-AGPAT) is an enzyme family composed of 11 isoforms. Notably, 1-AGPAT 2, the most studied isoform since its discovery, is a critical enzyme in the triglyceride synthesis pathway, converting lysophosphatidic acid to phosphatidic acid. In addition, AGPAT2 gene expression is shown to be essential for adipocyte development and maturation. Defects in AGPAT2 are responsible for significant pathophysiological alterations related to adipose tissue (AT). Pathogenic variants in this gene are the molecular etiology of Congenital Generalized Lipodystrophy type 1 (CGL1), in which fatty tissue is absent from birth. Metabolically, these individuals have several metabolic complications, including hypoleptinemia, hypoadiponectinemia, hyperglycemia, and hypertriglyceridemia. Furthermore, numerous AGPAT2 pathogenic variants that enormously affect the amino acid sequence, the tertiary structure of 1-AGPAT 2, and their transmembrane and functional domains were found in CGL1 patients. However, studies investigating the genotype-phenotype relationship in this disease are scarce. Here, we used bioinformatics tools to verify the effect of the main pathogenic variants reported in the AGPAT2 gene: c.366-588del, c.589-2A>G, c.646A>T, c.570C>A, c.369-372delGCTC, c.202C>T, c.514G>A, and c.144C>A in the 1-AGPAT 2 membrane topology. We also correlated the phenotype of CGL1 subjects harboring these variants to understand the genotype-phenotype relationship. We provided an integrative view of clinical, genetic, and metabolic features from CGL1 individuals, helping to understand the role of 1-AGPAT 2 in the pathogenesis of this rare disease. Data reviewed here highlight the importance of new molecular studies to improve our knowledge concerning clinical and genetic heterogeneity in CGL1.

#5

Muscle Rippling and Myoedema in CAVIN1-Related Congenital Generalized Lipodystrophy Type 4.

Neurology2025 Nov 11

Publicações recentes

Ver todas no PubMed

📚 EuropePMC196 artigos no totalmostrando 188

2026

Lipodystrophies in Clinical Practice: A Case Series From a Local Health Unit in Portugal.

Cureus
2026

Berardinelli-Seip syndrome.

Endokrynologia Polska
2025

AGPAT2 acts at the crossroads of lipid biosynthesis and DRP1-mediated ER morphogenesis.

Nature communications
2025

Case Report: Metreleptin treatment enables successful pregnancy in a female with congenital generalized lipodystrophy.

Frontiers in endocrinology
2025

"Seipin mediates Perilipin-1 recruitment to lipid droplets to preserve human adipocyte identity".

bioRxiv : the preprint server for biology
2025

Pathways to improving the awareness, diagnosis and management of lipodystrophy in Brazil: an expert panel discussion.

Diabetology &amp; metabolic syndrome
2025

Clinical and Genetic Insights into Congenital Generalized Lipodystrophy Type 4: A Case Report.

Molecular syndromology
2025

Epidemiological and clinical data from the European Lipodystrophy Registry.

European journal of endocrinology
2025

Calf skinfold measurements as a diagnostic tool for lipodystrophy syndromes: a cross-sectional study.

Diabetology &amp; metabolic syndrome
2025

Muscle Rippling and Myoedema in CAVIN1-Related Congenital Generalized Lipodystrophy Type 4.

Neurology
2025

Long-Term Clinical Experience With Metreleptin in a Brazilian Patient With Congenital Generalized Lipodystrophy Type 2.

JCEM case reports
2025

The clinical approach to child and adolescent patients with lipodystrophy: a series of international case discussions.

Frontiers in endocrinology
2025

Inherited Lipodystrophy Associated With POLD1 and CAVIN1 Mutations: Two Cases From the Indian Subcontinent.

Cureus
2025

Preliminary high-dose irradiation of the recipient and associated damage of bone marrow stromal compartment enables bone marrow stroma transplantation.

Scientific reports
2025

The Role of the AGPAT2 Gene in Adipose Tissue Biology and Congenital Generalized Lipodystrophy Pathophysiology.

International journal of molecular sciences
2025

The blood transcriptome of the human congenital generalized lipodystrophy.

Endocrine
2025

Diagnosis and Management of Genetic Lipodystrophy Syndromes and its Implications for Atherosclerosis.

Current atherosclerosis reports
2025

Tirzepatide for Congenital Generalized Lipodystrophy.

The New England journal of medicine
2025

A very low carbohydrate diet improved metabolic profile in congenital generalized lipodystrophy type 4.

Endocrinology, diabetes &amp; metabolism case reports
2024

Siblings With Berardinelli-Seip Congenital Lipodystrophy: Clinical Insights and Challenges.

Cureus
2024

A series of genetically confirmed congenital lipodystrophy and diabetes in adult southern Indian patients.

Scientific reports
2025

The spectrum of rippling muscle disease.

Muscle &amp; nerve
2025

Assessment of aortomesenteric distance and mesenteric and retroperitoneal adipose tissue thickness in genetic forms of lipodystrophy.

Journal of endocrinological investigation
2024

A Rare Case of Congenital Generalized Lipodystrophy.

Cureus
2024

Diagnosis, treatment and management of lipodystrophy: the physician perspective on the patient journey.

Orphanet journal of rare diseases
2024

Identification of ibuprofen targeting CXCR family members to alleviate metabolic disturbance in lipodystrophy based on bioinformatics and in vivo experimental verification.

Frontiers in endocrinology
2024

Congenital Generalized Lipodystrophy in a Division 1 Female Sprinter.

Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine
2024

Diagnostic and referral pathways in patients with rare lipodystrophy and insulin-resistance syndromes: key milestones assessed from a national reference center.

Orphanet journal of rare diseases
2024

Heterogeneity and high prevalence of bone manifestations, and bone mineral density in congenital generalized lipodystrophy subtypes 1 and 2.

Frontiers in endocrinology
2024

Regulated regeneration of adipose tissue in lipodystrophic Agpat2-null mice partially ameliorates hepatic steatosis.

iScience
2024

Analysis of disease characteristics of a large patient cohort with congenital generalized lipodystrophy from the Middle East and North Africa.

Orphanet journal of rare diseases
2024

Identification of genetic suppressors for a BSCL2 lipodystrophy pathogenic variant in Caenorhabditis elegans.

Disease models &amp; mechanisms
2024

Acquired generalized lipodystrophy in a juvenile dermatomyositis patient.

International journal of rheumatic diseases
2023

Across-species benefits of adrenalectomy on congenital generalized lipoatrophic diabetes: a review.

Frontiers in endocrinology
2024

Metabolic and other morbid complications in congenital generalized lipodystrophy type 4.

American journal of medical genetics. Part A
2024

Patients' perspective on the medical pathway from first symptoms to diagnosis in genetic lipodystrophy.

European journal of endocrinology
2023

Lysophosphatidic acid triggers inflammation in the liver and white adipose tissue in rat models of 1-acyl-sn-glycerol-3-phosphate acyltransferase 2 deficiency and overnutrition.

Proceedings of the National Academy of Sciences of the United States of America
2023

Identification of Genetic Suppressors for a Berardinelli-Seip Congenital Generalized Lipodystrophy Type 2 (BSCL2) Pathogenic Variant in C. elegans.

bioRxiv : the preprint server for biology
2023

Regulated adipose tissue-specific expression of human AGPAT2 in lipodystrophic Agpat2-null mice results in regeneration of adipose tissue.

iScience
2023

A murine model of BSCL2-associated Celia's encephalopathy.

Neurobiology of disease
2023

Isolated Congenital Lower Limb Lipoatrophy: A Case Report and Literature Review.

Plastic and reconstructive surgery. Global open
2023

Insulin Signaling Through the Insulin Receptor Increases Linear Growth Through Effects on Bone and the GH-IGF-1 Axis.

The Journal of clinical endocrinology and metabolism
2024

Lipodystrophic gene Agpat2 deficiency aggravates hyperlipidemia and atherosclerosis in Ldlr-/- mice.

Biochimica et biophysica acta. Molecular basis of disease
2023

Plasma signatures of Congenital Generalized Lipodystrophy patients identified by untargeted lipidomic profiling are not changed after a fat-containing breakfast meal.

Prostaglandins, leukotrienes, and essential fatty acids
2023

A new mutation in the CAVIN1/PTRF gene in two siblings with congenital generalized lipodystrophy type 4: case reports and review of the literature.

Frontiers in endocrinology
2023

Delayed Presentation of Berardinelli-Siep Lipodystrophy in an Adolescent Female.

Journal of investigative medicine high impact case reports
2023

Case report: Echocardiographic diagnosis of cardiac involvement caused by congenital generalized lipodystrophy in an infant.

Frontiers in pediatrics
2023

Clinical features of generalized lipodystrophy in Turkey: A cohort analysis.

Diabetes, obesity &amp; metabolism
2023

Perinatal, metabolic, and reproductive features in PPARG-related lipodystrophy.

European journal of endocrinology
2023

Identifying congenital generalized lipodystrophy using deep learning-DEEPLIPO.

Scientific reports
2023

Perilipin 1 Antibodies in Patients With Acquired Generalized Lipodystrophy.

Diabetes
2023

Features of BSCL2 related congenital generalized lipodystrophy in China: long-term follow-up of three patients and literature review.

Journal of pediatric endocrinology &amp; metabolism : JPEM
2022

A study of congenital generalized lipodystrophy (CGL) caused by BSCL2 gene mutation.

Yi chuan = Hereditas
2022

Unusual magnetic resonance imaging findings of cystic bone lesions in congenital generalized lipodystrophy.

Journal of postgraduate medicine
2022

Gene therapy restores adipose tissue and metabolic health in a pre-clinical mouse model of lipodystrophy.

Molecular therapy. Methods &amp; clinical development
2022

Reduced gut microbiota diversity in patients with congenital generalized lipodystrophy.

Diabetology &amp; metabolic syndrome
2022

Reduced phosphatidylcholine synthesis suppresses the embryonic lethality of seipin deficiency.

Life metabolism
2022

Impaired functional exercise capacity and greater cardiovascular response to the 6-min walk test in congenital generalized lipodystrophy.

BMC cardiovascular disorders
2022

Child With Congenital Generalized Lipodystrophy Type 4 for Electrophysiology Study and Catheter Ablation: Anesthetic Challenges.

Journal of cardiothoracic and vascular anesthesia
2022

Face-sparing Congenital Generalized Lipodystrophy Type 1 Associated With Nonclassical Congenital Adrenal Hyperplasia.

The Journal of clinical endocrinology and metabolism
2022

Lipodystrophy for the Diabetologist-What to Look For.

Current diabetes reports
2023

Metreleptin Treatment in a Boy with Congenital Generalized Lipodystrophy due to Homozygous c.465_468delGACT (p.T156Rfs*8) Mutation in the BSCL2 Gene: Results From the First-year.

Journal of clinical research in pediatric endocrinology
2022

Berardinelli Seip Syndrome: A rare case report.

JPMA. The Journal of the Pakistan Medical Association
2022

Congenital generalized lipodystrophy in two siblings from Saudi Arabia: A case report.

Clinical case reports
2022

Case Report: Precision COVID-19 Immunization Strategy to Overcome Individual Fragility: A Case of Generalized Lipodystrophy Type 4.

Frontiers in immunology
2022

Successful treatment of severe hypertriglyceridemia with icosapent ethyl in a case of congenital generalized lipodystrophy type 4.

Journal of pediatric endocrinology &amp; metabolism : JPEM
2022

Congenital generalized lipodystrophy type 4 due to a novel PTRF/CAVIN1 pathogenic variant in a child: effects of metreleptin substitution.

Journal of pediatric endocrinology &amp; metabolism : JPEM
2022

The neonatal onset diabetes mellitus of Chinese neonate with congenital generalized lipodystrophy 2: a case report.

BMC endocrine disorders
2022

Looking for the skeleton in the closet-rare genetic diagnoses in patients with diabetes and skeletal manifestations.

Acta diabetologica
2022

Type 2 congenital generalized lipodystrophy with a heterozygous missense NOTCH2 mutation.

European journal of clinical nutrition
2022

Lipid Metabolism in Cancer: The Role of Acylglycerolphosphate Acyltransferases (AGPATs).

Cancers
2021

AGPAT2 interaction with CDP-diacylglycerol synthases promotes the flux of fatty acids through the CDP-diacylglycerol pathway.

Nature communications
2021

RNA-seq of peripheral blood mononuclear cells of congenital generalized lipodystrophy type 2 patients.

Scientific data
2021

Biallelic CAV1 null variants induce congenital generalized lipodystrophy with achalasia.

European journal of endocrinology
2021

Reduced Endothelial Leptin Signaling Increases Vascular Adrenergic Reactivity in a Mouse Model of Congenital Generalized Lipodystrophy.

International journal of molecular sciences
2021

Bone Mineral Density in Congenital Generalized Lipodystrophy: The Role of Bone Marrow Tissue, Adipokines, and Insulin Resistance.

International journal of environmental research and public health
2021

Generalized lipoatrophy syndromes.

Presse medicale (Paris, France : 1983)
2021

Approach to Diagnosing a Pediatric Patient With Severe Insulin Resistance in Low- or Middle-income Countries.

The Journal of clinical endocrinology and metabolism
2021

Misdiagnosis of Paget's Disease of Bone in a Congenital Generalized Lipodystrophy Patient: Case Report.

Frontiers in endocrinology
2020

Metreleptin replacement treatment improves quality of life and psychological well-being in congenital generalized lipodystrophy.

The National medical journal of India
2021

Course of lipaemia retinalis in acquired generalised lipodystrophy.

BMJ case reports
2021

SARS-COV-2 infection outcomes in patients with congenital generalized lipodystrophy.

Diabetology &amp; metabolic syndrome
2021

Targeted massively parallel sequencing for congenital generalized lipodystrophy.

Archives of endocrinology and metabolism
2021

Celia's Encephalopathy (BSCL2-Gene-Related): Current Understanding.

Journal of clinical medicine
2021

Bscl2 Deficiency Does Not Directly Impair the Innate Immune Response in a Murine Model of Generalized Lipodystrophy.

Journal of clinical medicine
2021

Altered acylated ghrelin response to food intake in congenital generalized lipodystrophy.

PloS one
2021

A novel AGPAT2 mutation associated with a case of late-diagnosed congenital generalized lipodystrophy type 1.

Acta diabetologica
2020

Rare case of congenital generalized lipodystrophy type 1.

The Indian journal of medical research
2020

Metreleptin for the treatment of progressive encephalopathy with/without lipodystrophy (PELD) in a child with progressive myoclonic epilepsy: a case report.

Italian journal of pediatrics
2021

Focus on progressive myoclonic epilepsy in Berardinelli-Seip syndrome.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2020

Cavin1 Deficiency Causes Disorder of Hepatic Glycogen Metabolism and Neonatal Death by Impacting Fenestrations in Liver Sinusoidal Endothelial Cells.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)
2021

Eating behaviour in contrasting adiposity phenotypes: Monogenic obesity and congenital generalized lipodystrophy.

Obesity reviews : an official journal of the International Association for the Study of Obesity
2020

[Identification of a novel AGPAT2 variant in a Chinese patient with congenital generalized lipodystrophy type 1].

Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
2020

Absence of AGPAT2 impairs brown adipogenesis, increases IFN stimulated gene expression and alters mitochondrial morphology.

Metabolism: clinical and experimental
2020

[Multiple subcutaneous nodules for 46 days in an infant aged 66 days].

Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
2020

Homozygous LMNA p.R582H pathogenic variant reveals increasing effect on the severity of fat loss in lipodystrophy.

Clinical diabetes and endocrinology
2020

Berardinelli-Seip Syndrome and Essential Thrombocytosis: An Unusual Association.

Oman medical journal
2020

Unusual clinical features associated with congenital generalized lipodystrophy type 4 in a patient with a novel E211X CAVIN1 gene variant.

Clinical diabetes and endocrinology
2020

A rare frameshift mutation in the AGPAT2 gene in a family from gaza with congenital generalized lipodystrophy.

Clinical endocrinology
2020

Leu124Serfs*26, a novel AGPAT2 mutation in congenital generalized lipodystrophy with early cardiovascular complications.

Diabetology &amp; metabolic syndrome
2020

Novel compound heterozygous variant of BSCL2 identified by whole exome sequencing and multiplex ligation‑dependent probe amplification in an infant with congenital generalized lipodystrophy.

Molecular medicine reports
2020

High prevalence of congenital generalized lipodystrophy in Piura, Peru.

Intractable &amp; rare diseases research
2019

Retinopathy and Uveitis in Congenital Generalized Lipodystrophy with Hypertriglyceridemia and Uncontrolled Diabetes (Berardinelli-Seip Syndrome).

Middle East African journal of ophthalmology
2020

Oligomers of the lipodystrophy protein seipin may co-ordinate GPAT3 and AGPAT2 enzymes to facilitate adipocyte differentiation.

Scientific reports
2020

Acromegaly with congenital generalized lipodystrophy - two rare insulin resistance conditions in one patient: a case report.

Journal of medical case reports
2020

Early Left Ventricular Systolic Dysfunction Detected by Two-Dimensional Speckle-Tracking Echocardiography in Young Patients with Congenital Generalized Lipodystrophy.

Diabetes, metabolic syndrome and obesity : targets and therapy
2020

Metabolomic Analysis of the Effects of Leptin Replacement Therapy in Patients with Lipodystrophy.

Journal of the Endocrine Society
2020

Changes in redox and endoplasmic reticulum homeostasis are related to congenital generalized lipodystrophy type 2.

Biochimica et biophysica acta. Molecular and cell biology of lipids
2020

GPAT3 deficiency alleviates insulin resistance and hepatic steatosis in a mouse model of severe congenital generalized lipodystrophy.

Human molecular genetics
2019

Seipin-linked congenital generalized lipodystrophy type 2: a rare case with multiple lytic and pseudo-osteopoikilosis lesions.

Acta radiologica open
2020

Remember to assess the 'whole' patient: a further immune-related adverse event of programmed cell death 1 checkpoint inhibition.

The British journal of dermatology
2020

Neonatal cardiac hypertrophy: the role of hyperinsulinism-a review of literature.

European journal of pediatrics
2019

A New Compound Heterozygous Mutation Of BSCL2 In A Chinese Zhuang Ethnic Family With Congenital Generalized Lipodystrophy.

Diabetes, metabolic syndrome and obesity : targets and therapy
2020

Congenital generalized lipodystrophy: The evaluation of clinical follow-up findings in a series of five patients with type 1 and two patients with type 4.

European journal of medical genetics
2019

Medical management of a child with congenital generalized lipodystrophy accompanied with progressive myoclonic epilepsy: A case report.

Medicine
2019

Berardinelli Seip Congenital Lipodystrophy Syndrome: 10 Year Follow-up.

Indian pediatrics
2020

Interaction of cavin-1/PTRF leucine zipper domain 2 and its congenital generalized lipodystrophy mutant with model membranes.

Biochemical and biophysical research communications
2019

The long-term management of congenital generalized lipodystrophy (Berardinelli-Seip syndrome): the clinical manifestations of Japanese siblings for approximately 20 years.

Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology
2019

Leptin Restores Endothelial Function via Endothelial PPARγ-Nox1-Mediated Mechanisms in a Mouse Model of Congenital Generalized Lipodystrophy.

Hypertension (Dallas, Tex. : 1979)
2019

Association between cardiovascular autonomic neuropathy and left ventricular hypertrophy in young patients with congenital generalized lipodystrophy.

Diabetology &amp; metabolic syndrome
2019

Congenital lipodystrophy induces severe osteosclerosis.

PLoS genetics
2020

Acquired generalized lipodystrophy under immune checkpoint inhibition.

The British journal of dermatology
2019

Seipin deletion in mice enhances phosphorylation and aggregation of tau protein through reduced neuronal PPARγ and insulin resistance.

Neurobiology of disease
2019

Celia's encephalopathy and c.974dupG in BSCL2 gene: a hidden change in a known variant.

Neurogenetics
2019

Aggressive papillary thyroid carcinoma in a child with type 2 congenital generalized lipodystrophy.

Archives of endocrinology and metabolism
2019

Berardinelli-Seip syndrome and progressive myoclonus epilepsy.

Epileptic disorders : international epilepsy journal with videotape
2019

Metreleptin treatment for congenital generalized lipodystrophy type 4 (CGL4): a case report.

Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology
2019

Gene-gene and gene-environment interactions in lipodystrophy: Lessons learned from natural PPARγ mutants.

Biochimica et biophysica acta. Molecular and cell biology of lipids
2019

[Mutations in the BSCL2 gene cause congenital generalized lipodystrophy complicated by severe acute pancreatitis: a case report].

Zhonghua nei ke za zhi
2019

Type 2 Congenital Generalized Lipodystrophy: The Diagnosis is in Your Hands.

The Journal of pediatrics
2018

[Unusual facies and recurrent high triglycerides for more than one year in a girl].

Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
2019

A Patient with Berardinelli-Seip Syndrome, Novel AGPAT2 Splicesite Mutation and Concomitant Development of Non-diabetic Polyneuropathy.

Journal of clinical research in pediatric endocrinology
2019

Postmortem Findings in a Young Man With Congenital Generalized Lipodystrophy, Type 4 Due to CAVIN1 Mutations.

The Journal of clinical endocrinology and metabolism
2019

Adipose tissue transplantation ameliorates lipodystrophy-associated metabolic disorders in seipin-deficient mice.

American journal of physiology. Endocrinology and metabolism
2018

[A case report of congenital generalized lipodystrophy].

Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
2019

Monogenic forms of lipodystrophic syndromes: diagnosis, detection, and practical management considerations from clinical cases.

Current medical research and opinion
2019

Further delineation of AGPAT2 and BSCL2 related congenital generalized lipodystrophy in young infants.

European journal of medical genetics
2018

Impairment of respiratory muscle strength in Berardinelli-Seip congenital lipodystrophy subjects.

Respiratory research
2018

Characteristic findings of skeletal muscle MRI in caveolinopathies.

Neuromuscular disorders : NMD
2018

Expression of AGPAT2, an enzyme involved in the glycerophospholipid/triacylglycerol biosynthesis pathway, is directly regulated by HIF-1 and promotes survival and etoposide resistance of cancer cells under hypoxia.

Biochimica et biophysica acta. Molecular and cell biology of lipids
2018

Causes of death in patients with Berardinelli-Seip congenital generalized lipodystrophy.

PloS one
2018

Renal injury in Seipin-deficient lipodystrophic mice and its reversal by adipose tissue transplantation or leptin administration alone: adipose tissue-kidney crosstalk.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology
2018

Seipin deficiency in mice causes loss of dopaminergic neurons via aggregation and phosphorylation of α-synuclein and neuroinflammation.

Cell death &amp; disease
2019

Congenital generalized lipodystrophy in Taiwan.

Journal of the Formosan Medical Association = Taiwan yi zhi
2018

Anesthesia for patients with PTRF mutations: a case report.

JA clinical reports
2018

Early commitment of cardiovascular autonomic modulation in Brazilian patients with congenital generalized lipodystrophy.

BMC cardiovascular disorders
2018

Clinical outcome in a series of pediatric patients with congenital generalized lipodystrophies treated with dietary therapy.

Journal of pediatric endocrinology &amp; metabolism : JPEM
2017

Congenital Generalized Lipodystrophy Type 2 in a Patient From a High-Prevalence Area.

Journal of the Endocrine Society
2017

Determining residual adipose tissue characteristics with MRI in patients with various subtypes of lipodystrophy.

Diagnostic and interventional radiology (Ankara, Turkey)
2017

Metabolic, Reproductive, and Neurologic Abnormalities in Agpat1-Null Mice.

Endocrinology
2017

Clinical and molecular characterization of two Chinese patients with Type 2 congenital generalized lipodystrophy.

Gene
2017

Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study.

Neuromuscular disorders : NMD
2017

MECHANISTIC INSIGHTS INTO OSTEOPOROSIS IN PATIENTS WITH LIPODYSTROPHY AND REVIEW OF THE LITERATURE.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
2017

Normal bone density and trabecular bone score, but high serum sclerostin in congenital generalized lipodystrophy.

Bone
2017

Clinical Features and Management of Non-HIV-Related Lipodystrophy in Children: A Systematic Review.

The Journal of clinical endocrinology and metabolism
2017

High incidence of BSCL2 intragenic recombinational mutation in Peruvian type 2 Berardinelli-Seip syndrome.

American journal of medical genetics. Part A
2016

Characterization of a caveolin-1 mutation associated with both pulmonary arterial hypertension and congenital generalized lipodystrophy.

Traffic (Copenhagen, Denmark)
2016

Cardiac Manifestations of Congenital Generalized Lipodystrophy.

Clinical diabetes : a publication of the American Diabetes Association
2016

Progressive Myoclonus Epilepsy in Congenital Generalized Lipodystrophy type 2: Report of 3 cases and literature review.

Seizure
2016

Bone imaging findings in genetic and acquired lipodystrophic syndromes: an imaging study of 24 cases.

Skeletal radiology
2016

PTRF/Cavin-1 Deficiency Causes Cardiac Dysfunction Accompanied by Cardiomyocyte Hypertrophy and Cardiac Fibrosis.

PloS one
2017

Clinical and Mutational Features of Three Chinese Children with Congenital Generalized Lipodystrophy.

Journal of clinical research in pediatric endocrinology
2016

Assembly and Turnover of Caveolae: What Do We Really Know?

Frontiers in cell and developmental biology
2016

Neuronal seipin knockout facilitates Aβ-induced neuroinflammation and neurotoxicity via reduction of PPARγ in hippocampus of mouse.

Journal of neuroinflammation
2016

Raptor/mTORC1 loss in adipocytes causes progressive lipodystrophy and fatty liver disease.

Molecular metabolism
2016

Clinical Utility Gene Card for: Congenital Generalized Lipodystrophy.

European journal of human genetics : EJHG
2016

Spectrum of clinical manifestations in two young Turkish patients with congenital generalized lipodystrophy type 4.

European journal of medical genetics
2016

Maladaptative Autophagy Impairs Adipose Function in Congenital Generalized Lipodystrophy due to Cavin-1 Deficiency.

The Journal of clinical endocrinology and metabolism
2016

Natural History of Congenital Generalized Lipodystrophy: A Nationwide Study From Turkey.

The Journal of clinical endocrinology and metabolism
2016

Clinical and laboratory data of a large series of patients with congenital generalized lipodystrophy.

Diabetology &amp; metabolic syndrome
2016

Impaired adipogenic capacity in induced pluripotent stem cells from lipodystrophic patients with BSCL2 mutations.

Metabolism: clinical and experimental
2016

Successful cardiac transplantation in a patient with congenital generalized lipodystrophy.

Pediatric transplantation
2016

Activation of PPARγ Ameliorates Spatial Cognitive Deficits through Restoring Expression of AMPA Receptors in Seipin Knock-Out Mice.

The Journal of neuroscience : the official journal of the Society for Neuroscience
2015

Diet rich in Docosahexaenoic Acid/Eicosapentaenoic Acid robustly ameliorates hepatic steatosis and insulin resistance in seipin deficient lipodystrophy mice.

Nutrition &amp; metabolism
2016

One-year metreleptin improves insulin secretion in patients with diabetes linked to genetic lipodystrophic syndromes.

Diabetes, obesity &amp; metabolism
2016

Case report: Dental management of Berardinelli-Seip congenital lipodystrophy.

European archives of paediatric dentistry : official journal of the European Academy of Paediatric Dentistry
2015

Seipin knockout in mice impairs stem cell proliferation and progenitor cell differentiation in the adult hippocampal dentate gyrus via reduced levels of PPARγ.

Disease models &amp; mechanisms
2015

A Novel Syndrome of Generalized Lipodystrophy Associated With Pilocytic Astrocytoma.

The Journal of clinical endocrinology and metabolism
2015

Region-specific variation in the properties of skeletal adipocytes reveals regulated and constitutive marrow adipose tissues.

Nature communications
2015

Congenital generalized lipodystrophies--new insights into metabolic dysfunction.

Nature reviews. Endocrinology
2015

Acquired partial lipodystrophy is associated with increased risk for developing metabolic abnormalities.

Metabolism: clinical and experimental
2016

Congenital generalized lipodystrophy: identification of novel variants and expansion of clinical spectrum.

Clinical genetics
2015

Seipin is necessary for normal brain development and spermatogenesis in addition to adipogenesis.

Human molecular genetics
2015

Dysfunction of lipid metabolism in lipodystrophic Seipin-deficient mice.

Biochemical and biophysical research communications
2015

Lipodystrophies: adipose tissue disorders with severe metabolic implications.

Journal of physiology and biochemistry
2015

Expression of seipin in adipose tissue rescues lipodystrophy, hepatic steatosis and insulin resistance in seipin null mice.

Biochemical and biophysical research communications
2015

Seipin oligomers can interact directly with AGPAT2 and lipin 1, physically scaffolding critical regulators of adipogenesis.

Molecular metabolism
2015

Novel nonsense mutation in the PTRF gene underlies congenital generalized lipodystrophy in a consanguineous Saudi family.

European journal of medical genetics
Ver todos os 196 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Lipodistrofia generalizada congênita.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Lipodistrofia generalizada congênita

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Lipodystrophies in Clinical Practice: A Case Series From a Local Health Unit in Portugal.
    Cureus· 2026· PMID 41869101mais citado
  2. Berardinelli-Seip syndrome.
    Endokrynologia Polska· 2026· PMID 41841805mais citado
  3. AGPAT2 acts at the crossroads of lipid biosynthesis and DRP1-mediated ER morphogenesis.
    Nature communications· 2025· PMID 41387688mais citado
  4. The Role of the AGPAT2 Gene in Adipose Tissue Biology and Congenital Generalized Lipodystrophy Pathophysiology.
    International journal of molecular sciences· 2025· PMID 40508223mais citado
  5. Muscle Rippling and Myoedema in CAVIN1-Related Congenital Generalized Lipodystrophy Type 4.
    Neurology· 2025· PMID 41066720mais citado
  6. Gpat3 Knockout Attenuates Adipose Loss and Steatohepatitis in Agpat2-Deficient Mice.
    Am J Pathol· 2026· PMID 41881305recente
  7. Case Report: Metreleptin treatment enables successful pregnancy in a female with congenital generalized lipodystrophy.
    Front Endocrinol (Lausanne)· 2025· PMID 41341138recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:528(Orphanet)
  2. MONDO:0018883(MONDO)
  3. GARD:13388(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Q6556681(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Compêndio · Raras BR

Lipodistrofia generalizada congênita

ORPHA:528 · MONDO:0018883
Prevalência
1-9 / 1 000 000
Herança
Autosomal recessive
CID-10
E88.1 · Lipodistrofia não classificada em outra parte
CID-11
Ensaios
5 ativos
Início
Childhood, Infancy, Neonatal
Prevalência
0.5 (Europe)
MedGen
UMLS
C0011859
EuropePMC
Wikidata
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades